09:18 AM EDT, 04/10/2025 (MT Newswires) -- DexCom ( DXCM ) said Thursday the Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring System for people at least 18 years old with diabetes in the US.

The device features 15.5 days of wear and provides easier glucose management with fewer monthly sensors and lower monthly waste, the company said.

The company said it is working with its insulin pump partners to ensure the wearable's compatibility with automated insulin delivery systems upon launch, which is expected to take place in the US in H2.

DexCom ( DXCM ) shares were up 9.6% in premarket activity Thursday.